The Rare Pediatric Disease Priority Review Voucher program is one of the most important incentives for biopharmaceutical companies to develop new and life-changing treatments for pediatric neuromuscular diseases. This incentive, while continuing along in limited capacity, will cease to exist if not reauthorized by October 2026. 

There is real momentum behind reauthorizing the program as the House of Representatives passed the bill unanimously on December 1st, 2025. Now we need the Senate to act! 

Please contact your Senators and tell them that they need to reauthorize this critical incentive by the holiday break. Remember to personalize the message on why pediatric neuromuscular disease drug development is important to you.